Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for CVID Enteropathy
NCT02199496Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2015
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab in common variable immunodeficiency (CVID), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2015; status: completed.
02
Drugs
ustekinumab
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on NCT02199496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199496.